﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>Silicon Investor - American BioMed (ABMI) a strong buy recommendation of $5-6</title><copyright>Copyright © 2026 Knight Sac Media.  All rights reserved.</copyright><link>https://www.siliconinvestor.com/subject.aspx?subjectid=5464</link><description>
Does anyone have any info on this one?      THE WOODLANDS, Texas--(BUSINESS WIRE)--June 6, 1996--Strategic  Advisory Inc. announced today that they have initiated coverage on  American BioMed Inc. (OTC BB: ABMI), of The Woodlands, Texas.           Strategic has instituted a strong buy recommendation with a 12  to 18 month target valuation of $5 to $6 per share.  The company  analyst stated that American BioMed Inc. will be highlighted in  Strategic's mid-June newsletter as well as the August publication of  Individual Investor.           ABMI is a company that is just beginning to commercialize its  vascular product lines.  These products include but are not limited  to patented and unique products such as stents, catheters and the  OmniCath, ABMI's atherectomy catheter.           Stents are the new wave in cardiology.  These small devices use  self-expanding nitinol that helps keep blood vessels open after an  angioplasty has been performed.  This does not infringe on Johnson &amp;  Johnson's (NYSE:JNJ) balloon delivered stents.  ABMI is also  positioning itself as the premier provider of silicone based  catheters.  Their nine FDA approved catheters are silicone based and  have broad uses.           The OmniCath is an atherectomy device which actually removes  plaque buildup from blood vessels.  It vacuums and filters preventing distally embolisms and thereby helps return blood flow back to normal levels.  The analyst also cites added valuation due to the recent  stock acquisition of InStent Inc. (NASDAQ:ININ) for $214.6 million  by Medtronic Inc. (NYSE:MDT) due to the similarity of the stent  delivery systems of InStent and American BioMed.           The OmniCath is currently being marketed in Europe and is in  stage two of the FDA approval process and is about to submit its  510-K filing in order to speed up the process which will fully  commercialize the unit in the United States.           --30--eh/sf*  cmf/sf       CONTACT:        Strategic Advisory Inc.       Brendon Gebben, 800/793-2601</description><image><url>https://www.siliconinvestor.com/images/Logo380x132.png</url><title>SI - American BioMed (ABMI) a strong buy recommendation of $5-6</title><link>https://www.siliconinvestor.com/subject.aspx?subjectid=5464</link><width>380</width><height>132</height></image><ttl>10</ttl></channel></rss>